Lymphoma, B-cell
Showing 1 - 25 of >10,000
Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))
Not yet recruiting
- Lymphoma, B-Cell
- +7 more
- Adaptive Bridging Radiation Therapy (ABRT)
-
Boston, MassachusettsDana-Farber Cancer Institute
Aug 16, 2023
Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Not yet recruiting
- Lymphoma, B-Cell
- +6 more
- Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)
-
Guayaquil, Guayas, EcuadorInstituto Oncológico Nacional Dr. Juan Tanca Marengo
Apr 27, 2023
Communication Training Intervention for Large B-Cell Lymphoma
Recruiting
- Lymphoma, B-Cell
- +5 more
- Hematolo-GIST Training
- Participants Appointment
-
New York, New York
- +2 more
Jul 3, 2023
High-Dose Methotrexate Clearance in Diffuse Large B-Cell
Recruiting
- Central Nervous System Lymphoma
- Diffuse Large B-Cell Lymphoma
- Non-Interventional Study
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Sep 8, 2023
Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)
Not yet recruiting
- Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
- (no location specified)
Sep 5, 2023
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- +2 more
- CD19/CD22-bispecific CAR-T cells
-
Beijing, Beijing, ChinaLiang Wang
Oct 7, 2023
B-cell Non-Hodgkin's Lymphoma Trial (SHR-A1912; R-Chemo)
Not yet recruiting
- B-cell Non-Hodgkin's Lymphoma
- SHR-A1912; R-Chemo
- (no location specified)
Oct 23, 2023
Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,
Recruiting
- Diffuse Large B-cell Lymphoma Recurrent
- Diffuse Large B Cell Lymphoma Refractory
- Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Oct 12, 2023
Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)
Not yet recruiting
- Follicular Lymphoma
- +3 more
- Tazemetostat Pill
-
New York, New YorkWeill Cornell Medicine/NewYork-Presbyterian Hospital
Jun 28, 2023
Relmacabtagene Autoleucel in Patients With LBCL
Recruiting
- Large B-cell Lymphoma
- Relmacabtagene Autoleucel
-
Shanghai, Shanghai, ChinaRuijin Hospital Affiliated to Shanghai Jiao Tong University Scho
Nov 15, 2023
Non-hodgkin Lymphoma Trial (HY004)
Not yet recruiting
- Non-hodgkin Lymphoma
- HY004
- (no location specified)
Aug 21, 2023
Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)
Active, not recruiting
- Relapsed or Refractory Diffuse Large B-cell Lymphoma
- BEBT-908 for injection
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023
Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-cell Lymphoma
- RC19D2 cell injection
-
Tianjin, Tianjin, ChinaHematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023
Diffuse Large B Cell Lymphoma Trial in Rouen (Measure of the circulating tumor DNA)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Measure of the circulating tumor DNA
-
Rouen, FranceCentre Henri Becquerel
Nov 17, 2023
DLBCL Trial (Polatuzumab Vedotin)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Polatuzumab Vedotin
- (no location specified)
Jul 12, 2023
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell Trial in United Kingdom (ALETA-001)
Not yet recruiting
- Lymphoma, Non-Hodgkin
- +4 more
-
Birmingham, United Kingdom
- +5 more
Sep 18, 2023
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)
Recruiting
- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma
- CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital
Nov 19, 2023
Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)
Not yet recruiting
- Relapsed/Refractory B-Cell Lymphoma
- FT522
- +4 more
- (no location specified)
Jul 10, 2023
Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)
Recruiting
- Diffuse Large B Cell Lymphoma
- Zanubrutinib, Polatuzumab vedotin and Rituximab
-
Shanghai, Shanghai, ChinaZhongshan Hospital,Fudan University
Jul 10, 2023
CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma
Active, not recruiting
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- DISEASE
- (no location specified)
May 4, 2023
DLBCL Trial (Acalabrutinib, Rituximab)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Acalabrutinib
- Rituximab
- (no location specified)
Jul 11, 2023
Relapsed or Refractory B-cell Lymphoma Trial (Relmacabtagene Autoleucel Injection)
Not yet recruiting
- Relapsed or Refractory B-cell Lymphoma
- Relmacabtagene Autoleucel Injection
- (no location specified)
Apr 13, 2023
Primary Mediastinal Large B-cell Lymphoma With CNS Involvement
Recruiting
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
-
Milan, ItalyOspedale San Raffaele
Aug 29, 2023